Pharvaris N.V.(US:PHVS) Seeking Alpha·2025-12-03 22:43Core Insights - The announcement pertains to the topline data from the RAPIDe-3 Phase III clinical study of deucrictibant, which is an immediate-release capsule designed for the on-demand treatment of hereditary angioedema attacks [2]. Company Overview - Pharvaris is leading the communication regarding the RAPIDe-3 study and its implications for the treatment of hereditary angioedema [2]. - The webcast is part of Pharvaris's efforts to keep investors informed about the progress and potential of their clinical studies [2]. Clinical Study Details - The RAPIDe-3 study is a Phase III clinical trial, indicating it is in the later stages of testing before potential regulatory approval [2]. - The focus of the study is on the efficacy of deucrictibant in treating hereditary angioedema attacks on an on-demand basis [2].